Pharmacies need FDA-registered suppliers, contaminant testing and MedWatch reporting. A UVA doctor told AJMC gray-market vials often hold 5% to 75% of the labeled dose.
Recap by typeshit. Full story at The American Journal of Managed Care.
AP sources say FDA scientists opposed the HHS draft telling the agency not to act against pharmacies compounding six wellness peptides. Comments are open for two weeks.
Law firm Frier Levitt reads the rule as single-ingredient only, so the popular blend stays out. Public Citizen and ex-FDA official Janet Woodcock voice safety concerns.
Six peptides can now be compounded under strict conditions, but HHS itself says that proves nothing on safety, and research-use-only sellers stay outside the policy.
Compounders get a pass on BPC-157, TB-500 and four others if they meet sourcing and reporting rules. The Alliance for Pharmacy Compounding cheers it, while Public Citizen calls it reckless.
The industrialist names pharma, obesity clinics and personal fitness among the sectors he expects to gain from wider GLP-1 use.
Hims & Hers and a peptide academy met White House reviewers before release, and the Partnership for Safe Medicines has petitioned the FDA to block it.
Loading…